← 返回前沿论文

通过 CD39 下调增强 CAR T 细胞功能与代谢

英文原题:Augmenting CAR T cell functionality and metabolism through CD39 downtuning.

PubMed 2026/06/17(内容时间) Mol Ther Oncol Q1 · IF 8.5(JCR 2025)

研究概要

CD39/CD73轴是T细胞功能的有效内在抑制因子。

中文摘要

CD39/CD73轴是T细胞功能强大的内在抑制因子。CAR T细胞激活触发CD39升高;与常规CAR T细胞相比,CD39低表达CAR T细胞中CD39的下调减少了细胞外ATP降解,并增强了功能能力,表现为在重复CAR刺激下颗粒酶/穿孔素增加和脱颗粒增强。此外,CD39低表达CAR T细胞表现出更优的线粒体功能和增强的糖酵解活性。因此,在异种移植NSG小鼠中,CD39低表达CAR T细胞在控制CEA+胃癌方面优于常规CAR T细胞。CD39效应是独特的,因为同样参与耗竭调节的CD38下调在刺激性“应激条件”下并未提供益处。激活诱导的CD39/CD73上调促成了CAR T细胞的负反馈环路;CD39水平下调通过减少AMP和腺苷介导的抑制,增强了T细胞抗肿瘤活性。在更广泛的背景下,CD39下调不太可能作为单一干预在所有情况下都足够,但作为联合策略的一部分,与靶向其他代谢或免疫检查点通路的互补方法结合,以进一步增强CAR T细胞持久性和抗肿瘤活性,可能特别有价值。

展开英文摘要原文

The CD39/CD73 axis is a potent intrinsic repressor of T cell functionality. CAR T cell activation triggers the increase of CD39; its downregulation reduced extracellular ATP degradation and enhanced the functional capacities in CD39 low CAR T cells compared with conventional CAR T cells with respect to an increase in granzyme/perforin and degranulation upon repetitive CAR stimulation. CD39 low CAR T cells, moreover, displayed superior mitochondrial function and enhanced glycolytic activities. Consequently, CD39 low CAR T cells outperformed conventional CAR T cells in controlling CEA + gastric carcinoma in xeno-transplanted NSG mice. The CD39 effect is unique, since downtuning CD38, also involved in the regulation of exhaustion, did not provide benefits under stimulatory "stress conditions". Activation-induced upregulation of CD39/CD73 contributes to a negative feedback loop for CAR T cells; downregulated CD39 levels augmented T cell anti-tumor activities by reducing AMP and adenosine-mediated repression. In the broader context, CD39 downregulation is unlikely to be sufficient as a standalone intervention in all settings but may be particularly valuable as part of combination strategies with complementary approaches targeting additional metabolic or immune checkpoint pathways to further enhance CAR T cell persistence and anti-tumor activity.

论文信息

作者
Harrer DC、Baldwin J、Barden M、Pan H、Gergely B、Szöőr Á、Vereb G、Herr W
第一作者单位
Department of Hematology and Internal Oncology, University Hospital Regensburg, 93053 Regensburg, Germany.Germany
通讯作者单位
Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Chair Genetic Immunotherapy, University Regensburg, 93053 Regensburg, Germany.Germany
期刊
Molecular therapy. Oncology2026 Sep 17
原文标识
PubMed 42440466 · DOI 10.1016/j.omton.2026.201277